Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Pulmonary Diseases Clear all
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

NCT03002389
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Anoro Ellipta, Arnuity Ellipta
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Keswick, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

NCT02336425
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Kingwood, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

NCT00224406
View directory record Official record
Conditions
Ischemia-Reperfusion Injury, Lung Transplantation
Interventions
Repertaxin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Bronchiectasis

NCT00943514
View directory record Official record
Conditions
Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
AB308, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02439450
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Biological · Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

NCT01437878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions
Iloprost, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis

NCT01199887
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
IW001
Drug
Lead sponsor
ImmuneWorks
Industry
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

NCT01313663
View directory record Official record
Conditions
Lung Cancer, Small Cell
Interventions
pazopanib, pemetrexed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Tucson, Arizona • Skokie, Illinois • Indianapolis, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

NCT00159887
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
26
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

NCT02027428
View directory record Official record
Conditions
Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions
Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
91
States / cities
Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Not yet recruiting Not applicable Interventional

PRECISION-CPR: PRecision-Controlled Ventilation in CPR

NCT07088120
View directory record Official record
Conditions
Cardiac Arrest (CA)
Interventions
Precision-Controlled Ventilation with Real-Time Feedback, Standard Manual Ventilation During CPR
Device · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Results available

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00656305
View directory record Official record
Conditions
Bone Metastases, Multiple Myeloma
Interventions
ExAblate MRfFUS, Sham
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kidney Disease After COVID-19

NCT05328986
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Chronic Kidney Injury
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

NCT03818854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Human Mesenchymal Stromal Cells, Cell Reconstitution Media
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Not listed No phase listed Observational

A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients

NCT02087761
View directory record Official record
Conditions
Respiratory Tract Infection, Bronchitis, Pneumonia
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
3
States / cities
St Louis, Missouri • Lake Success, New York • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 17, 2026, 5:14 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 5:14 AM EDT